Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.
about
Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubesSpectroscopic and computational investigation of actinium coordination chemistryCerenkov luminescence imaging of medical isotopes.Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells.An overview of targeted alpha therapy.Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions.Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody.Cancer radioimmunotherapy.DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.Molecular targeted α-particle therapy for oncologic applications.Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization.Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Unconventional nuclides for radiopharmaceuticalsSelf-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery.The synthesis and application of polyamino polycarboxylic bifunctional chelating agents.Actinium-225 in targeted alpha-particle therapeutic applications.Tumour targeting with radiometals for diagnosis and therapy.The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.A nuclear chocolate box: the periodic table of nuclear medicine.Octadentate picolinic acid-based bispidine ligand for radiometal ions.A review of solute encapsulating nanoparticles used as delivery systems with emphasis on branched amphipathic peptide capsules.The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides.Branched amphiphilic peptide capsules: cellular uptake and retention of encapsulated solutes.6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.Active actinium.An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy.Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
P2860
Q28384090-BF27CC01-C897-4C8D-94B6-E9378EA7320FQ28829564-EAEC1E3D-37B8-4AC3-B1B3-C5C83579C258Q30499280-7E89265B-1433-45F5-9E62-8289FC67AEA2Q33455875-96E5ED17-6DE1-4866-BEF1-FD15953E7CB3Q34238513-BAD9BEBB-48BE-49FA-918C-45CBD23F8E66Q34460892-CEC2CDEE-B81E-4838-8217-EB36609BF534Q34555716-A8064D88-468F-4FAC-82D2-841989FB612AQ35070045-E2B8AEFB-A510-4130-842C-5940489EF40BQ35091643-D649337E-5DA4-417F-A966-00B911CE5222Q35814989-B1A9BAAB-7060-4D13-9C09-8A923F99F407Q36723768-9C9D2C80-44F7-4DC6-B7A2-E670E2AED81CQ37085052-FC09613B-25D0-4140-B636-075E7E1FDA10Q37129181-D01BD667-6DDC-4C59-9834-7483725E5A49Q37233043-E3498EA4-6859-4342-82EB-7257AB3555BEQ37850696-6AB6A2E1-929A-44BC-9647-58AD548538ADQ37971807-CC58A467-C9A5-45F1-9102-EFD989A321FAQ38100112-3577F7D7-781F-4143-AF8F-26202D2ED887Q38215613-83A36A8F-180E-41D7-B977-B524D73A779EQ38269216-6E307BC8-C621-42CF-99C0-E07823DAEBF1Q38620836-8C6D9A2E-E332-4B19-BE27-09A13AADBB56Q38754657-F474496D-5461-4F56-8A42-EC7F83391BB4Q41431969-9151CC87-E5CD-4F96-B76F-81D7E3D1BB5DQ42174106-B0BA6942-F2D1-4FAE-8E9E-000932F98CFCQ42732008-BCB60FE2-A6C4-4F60-807E-A9974E00299BQ46809132-66AF45CF-3817-429F-850D-3E3B30B670C6Q48265569-7D76400C-5700-41E9-8FF9-413D3580C66EQ55709954-FC5C3EA3-506E-4E31-B579-5DD73371558E
P2860
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Realizing the potential of the ...... particle therapy applications.
@ast
Realizing the potential of the ...... particle therapy applications.
@en
type
label
Realizing the potential of the ...... particle therapy applications.
@ast
Realizing the potential of the ...... particle therapy applications.
@en
prefLabel
Realizing the potential of the ...... particle therapy applications.
@ast
Realizing the potential of the ...... particle therapy applications.
@en
P2093
P2860
P1476
Realizing the potential of the ...... particle therapy applications.
@en
P2093
David A Scheinberg
Matthias Miederer
Michael R McDevitt
P2860
P304
P356
10.1016/J.ADDR.2008.04.009
P407
P577
2008-04-23T00:00:00Z